FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311753508> ?p ?o ?g. }

• W4311753508 abstract "Abstract Background Anti-retroviral therapy (ART) has been associated with significant weight gain and metabolic derangements in persons with HIV (PWH), and many PWH on ART experience comorbid obesity. GLP-1 receptor agonists (GLP-1RA) are used to treat type-2 diabetes and obesity in people without HIV infection, but data on the use of these agents in PWH on ART are limited. Methods We extracted data from electronic medical records of PWH on ART receiving care at a clinic in New Orleans, LA who had been started on GLP-1RA therapy. We tracked weight (change in body weight, body mass index [BMI]) and changes in hemoglobin A1c (Hba1c) over time from initiation of GLP-1RA to April 2022. A control group of PWH on metformin only will be compared to those on GLP-1RA at a later stage of analysis. Results Of 35 PWH on GLP-1RA, the mean age was 55.2 (standard deviation [SD] 10.0); 29 (83%) were Black/African American, 14 (40%) were assigned female at birth, 21 (60%) were assigned male at birth, and 2 were non-binary. Average BMI was 35.7 (SD 9.8) and average HbA1c was 9.5 (SD 2.6) at baseline. Integrase inhibitors were prescribed for 31 (89%) and metformin was prescribed for 20 (57%). Other baseline characteristics are shown in Figure 1. Mean duration of GLP-1RA therapy was 20.6 months (SD 14.0), and 20 (57%) had greater than 12 months of follow-up. Most (23, 66%) on GLP-1RA lost weight, 3 (9%) had a stable weight, and 9 (26%) gained weight. Five percent or more of body weight was lost by 11 (31%) of the total cohort (those with any amount of time on GLP-1RA) and by 9/20 (45%) of those on GLP-1RA for more than 12 months. Conclusion Our data show moderate weight loss among PWH on GLP-1RA. This study is limited by small sample size and limited follow-up time. Further research is needed to determine whether GLP-1RAs are an effective treatment option for obesity in PWH. Disclosures Meredith E. Clement, MD, Gilead Sciences: Grant/Research Support|Roche: Advisor/Consultant|Viiv Healthcare: Advisor/Consultant|Viiv Healthcare: Grant/Research Support." @default.
• W4311753508 created "2022-12-28" @default.
• W4311753508 creator A5018538259 @default.
• W4311753508 creator A5029373008 @default.
• W4311753508 creator A5044636000 @default.
• W4311753508 creator A5052088900 @default.
• W4311753508 creator A5089825873 @default.
• W4311753508 creator A5091781019 @default.
• W4311753508 date "2022-12-01" @default.
• W4311753508 modified "2023-09-30" @default.
• W4311753508 title "443. Do people living with HIV lose weight on GLP-1 agonist therapy?" @default.
• W4311753508 doi "https://doi.org/10.1093/ofid/ofac492.518" @default.
• W4311753508 hasPublicationYear "2022" @default.
• W4311753508 type Work @default.
• W4311753508 citedByCount "0" @default.
• W4311753508 crossrefType "journal-article" @default.
• W4311753508 hasAuthorship W4311753508A5018538259 @default.
• W4311753508 hasAuthorship W4311753508A5029373008 @default.
• W4311753508 hasAuthorship W4311753508A5044636000 @default.
• W4311753508 hasAuthorship W4311753508A5052088900 @default.
• W4311753508 hasAuthorship W4311753508A5089825873 @default.
• W4311753508 hasAuthorship W4311753508A5091781019 @default.
• W4311753508 hasBestOaLocation W43117535081 @default.
• W4311753508 hasConcept C126322002 @default.
• W4311753508 hasConcept C134018914 @default.
• W4311753508 hasConcept C142462285 @default.
• W4311753508 hasConcept C203014093 @default.
• W4311753508 hasConcept C2777180221 @default.
• W4311753508 hasConcept C2779306644 @default.
• W4311753508 hasConcept C2780221984 @default.
• W4311753508 hasConcept C2780323712 @default.
• W4311753508 hasConcept C2993143319 @default.
• W4311753508 hasConcept C3013748606 @default.
• W4311753508 hasConcept C511355011 @default.
• W4311753508 hasConcept C555293320 @default.
• W4311753508 hasConcept C71924100 @default.
• W4311753508 hasConceptScore W4311753508C126322002 @default.
• W4311753508 hasConceptScore W4311753508C134018914 @default.
• W4311753508 hasConceptScore W4311753508C142462285 @default.
• W4311753508 hasConceptScore W4311753508C203014093 @default.
• W4311753508 hasConceptScore W4311753508C2777180221 @default.
• W4311753508 hasConceptScore W4311753508C2779306644 @default.
• W4311753508 hasConceptScore W4311753508C2780221984 @default.
• W4311753508 hasConceptScore W4311753508C2780323712 @default.
• W4311753508 hasConceptScore W4311753508C2993143319 @default.
• W4311753508 hasConceptScore W4311753508C3013748606 @default.
• W4311753508 hasConceptScore W4311753508C511355011 @default.
• W4311753508 hasConceptScore W4311753508C555293320 @default.
• W4311753508 hasConceptScore W4311753508C71924100 @default.
• W4311753508 hasIssue "Supplement_2" @default.
• W4311753508 hasLocation W43117535081 @default.
• W4311753508 hasLocation W43117535082 @default.
• W4311753508 hasOpenAccess W4311753508 @default.
• W4311753508 hasPrimaryLocation W43117535081 @default.
• W4311753508 hasRelatedWork W2033313326 @default.
• W4311753508 hasRelatedWork W2291302444 @default.
• W4311753508 hasRelatedWork W2350153196 @default.
• W4311753508 hasRelatedWork W2464808367 @default.
• W4311753508 hasRelatedWork W2745151107 @default.
• W4311753508 hasRelatedWork W3116386123 @default.
• W4311753508 hasRelatedWork W4224241656 @default.
• W4311753508 hasRelatedWork W4251583039 @default.
• W4311753508 hasRelatedWork W4424148 @default.
• W4311753508 hasRelatedWork W1920632900 @default.
• W4311753508 hasVolume "9" @default.
• W4311753508 isParatext "false" @default.
• W4311753508 isRetracted "false" @default.
• W4311753508 workType "article" @default.